Professor Niazi Proposes New FDA Pathway to Increase Access to Expensive Medications Globally

Expanding Access to Medicines: Professor Niazi's Vision

In a groundbreaking move, Professor Sarfaraz K. Niazi from the College of Pharmacy and Pharmaceutical Sciences at Washington State University has taken a bold step toward enhancing accessibility to high-cost medications worldwide. On August 25, 2026, he submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA), advocating for the establishment of a unified scientific framework that would revolutionize the development of follow-on versions of FDA-approved medications.

The Current Landscape of Drug Accessibility

High-cost medications, particularly biological products and advanced therapies, remain economically inaccessible to a significant portion of the global population. Despite significant scientific advancements, approximately 80% of the world's population finds itself unable to afford cutting-edge treatments. Professor Niazi believes that without effective and accessible pathways for competitive medications, the promise of scientific innovation remains unfulfilled.

The Citizen Petition

Entitled "Request to Establish a Unified Reference-Anchored Equivalence Framework for Follow-On Human Drug and Biological Products," the petition calls for an expansion of the scientific rationale behind generics and biosimilars. This broader framework would encompass any FDA-approved drugs and biological products as permitted by existing legislation. With the expiration of patent and exclusivity protections, the petition aims to minimize barriers to market entry for follow-on products.

In laying out his argument, Niazi highlights a compelling aspect of drug manufacturing: if a medicine has been consistently manufactured for commercial use and its clinically relevant characteristics are reliable, why should the process be slowed by repetitive development studies that add little scientific value? This insight is pivotal as it challenges existing practices, paving the way for more agile and responsive drug development processes.